Table 1. Characteristics of probable CAPA cases.

CAPA: COVID-19-associated pulmonary aspergillosis; DM: diabetes mellitus; APACHE: Acute Physiology and Chronic Health Evaluation; NUTRIC: Nutrition Risk in Critically Ill; SOFA: Sequential Organ Failure Assessment; SAPS: Simplified Acute Physiology Score; ICU: intensive care unit; SD: standard deviation

Variables	Values (n=61)
Demographic data
Age in years (mean ±SD)	60.7 ±8.7
Gender ratio (male:female)	29:32
Smoking history (n=80), % (n)	27.9% (n=17)
Hypertension, % (n)	49.2% (n=30)
Risk factors for CAPA, % (n)
DM	73.8% (n=45)
Cirrhosis	8.2% (n=5)
≥2 comorbidities	90.2% (n=55)
Malignancy	21.3% (n=13)
Clinical variables
APACHE II, median (IQR)	14 (10-21)
NUTRIC score, median (IQR)	4 (2-6)
SOFA score, median (IQR)	4 (4-7)
SAPS, median (IQR)	33 (27-45)
Aspergillus fumigatus, % (n)	78.7% (n=48)
Aspergillus flavus, % (n)	16.4% (n=10)
Aspergillus terreus, % (n)	3.3% (n=2)
Aspergillus niger, % (n)	1.6% (n=1)
Treatment and clinical course
Remdesivir, % (n)	57.4% (n=35)
Tocilizumab, % (n)	54.1% (n=33)
Dexamethasone/methylprednisolone, % (n)	100% (n=61)
Voriconazole, % (n)	100% (n=61)
Lipid formulation amphotericin, % (n)	3.3% (n=2)
Vasopressors, % (n)	70.5% (n=43)
ICU days, median (IQR)	11 (4-14)
Death, % (n)	91.8% (n=56)